24-h Efficacy of Glaucoma Treatment Options

被引:0
|
作者
Anastasios G. P. Konstas
Luciano Quaranta
Banu Bozkurt
Andreas Katsanos
Julian Garcia-Feijoo
Luca Rossetti
Tarek Shaarawy
Norbert Pfeiffer
Stefano Miglior
机构
[1] Aristotle University of Thessaloniki,1st University Department of Ophthalmology
[2] Aristotle University of Thessaloniki,3rd University Department of Ophthalmology
[3] University of Brescia,Glaucoma Unit
[4] Selcuk University,Department of Ophthalmology
[5] University of Ioannina,Department of Ophthalmology
[6] University of Madrid,Eye Clinic, San Paolo Hospital
[7] University of Milan,Glaucoma Sector
[8] University of Geneva,Department of Ophthalmology
[9] University of Mainz,undefined
[10] University Bicocca of Milan,undefined
来源
Advances in Therapy | 2016年 / 33卷
关键词
24-h efficacy; 24-h intraocular pressure control; Circadian intraocular pressure characteristics; Diurnal intraocular pressure; Glaucoma therapy options; Intraocular pressure monitoring; Ophthalmology;
D O I
暂无
中图分类号
学科分类号
摘要
Current management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss. In the published literature, the hypothesis is often made that IOP control implies a single IOP measurement over time. Although the follow-up of glaucoma patients with single IOP measurements is quick and convenient, such measurements often do not adequately reflect the untreated IOP characteristics, or indeed the quality of treated IOP control during the 24-h cycle. Since glaucoma is a 24-h disease and the damaging effect of elevated IOP is continuous, it is logical that we should aim to understand the efficacy of all treatment options throughout the 24-h period. This article first reviews the concept and value of diurnal and 24-h IOP monitoring. It then critically evaluates selected available evidence on the 24-h efficacy of medical, laser and surgical therapy options. During the past decade several controlled trials have significantly enhanced our understanding on the 24-h efficacy of all glaucoma therapy options. Nevertheless, more long-term evidence is needed to better evaluate the 24-h efficacy of glaucoma therapy and the precise impact of IOP characteristics on glaucomatous progression and visual prognosis.
引用
收藏
页码:481 / 517
页数:36
相关论文
共 50 条
  • [21] Sustained Release of an Anti-Glaucoma Drug: Demonstration of Efficacy of a Liposomal Formulation in the Rabbit Eye
    Natarajan, Jayaganesh V.
    Chattopadhyay, Sujay
    Ang, Marcus
    Darwitan, Anastasia
    Foo, Selin
    Zhen, Ma
    Koo, Magdalene
    Wong, Tina T.
    Venkatraman, Subbu S.
    PLOS ONE, 2011, 6 (09):
  • [22] China Glaucoma Treatment Pattern Study I-Primary Angle-Closure Glaucoma: protocol for a multicentre, retrospective, observational study
    Chen, Jinyuan
    Du, Jie
    Xing, Xiaoli
    Liu, Danyan
    Jia, Zhiyang
    Zheng, Yajuan
    Wang, Dan
    Guo, Wenyi
    Jiang, Jian
    Duan, Guoping
    Tang, Li
    Wu, Zhengzheng
    Lv, Peng
    Ma, Jianjun
    Zhu, Yihua
    Liang, Yuanbo
    Sun, Xin
    He, Mingguang
    BMJ OPEN, 2023, 13 (04):
  • [23] Optical Coherence Tomography Analysis Based Prediction of Humphrey 24-2 Visual Field Thresholds in Patients With Glaucoma
    Guo, Zhihui
    Kwon, Young H.
    Lee, Kyungmoo
    Wang, Kai
    Wahle, Andreas
    Alward, Wallace L. M.
    Fingert, John H.
    Bettis, Daniel I.
    Johnson, Chris A.
    Garvin, Mona K.
    Sonka, Milan
    Abramoff, Michael D.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (10) : 3975 - 3985
  • [24] Bilateral Acute Angle-Closure Glaucoma Following Treatment with Topiramate for Headache
    Kulkarni C.
    Chaudhuri U.R.
    Jagathesan A.
    Neurology and Therapy, 2013, 2 (1-2) : 57 - 62
  • [25] Canaloplasty in the Treatment of Open-Angle Glaucoma: A Review of Patient Selection and Outcomes
    Riva, Ivano
    Brusini, Paolo
    Oddone, Francesco
    Michelessi, Manuele
    Weinreb, Robert N.
    Quaranta, Luciano
    ADVANCES IN THERAPY, 2019, 36 (01) : 31 - 43
  • [26] Canaloplasty in the Treatment of Open-Angle Glaucoma: A Review of Patient Selection and Outcomes
    Ivano Riva
    Paolo Brusini
    Francesco Oddone
    Manuele Michelessi
    Robert N. Weinreb
    Luciano Quaranta
    Advances in Therapy, 2019, 36 : 31 - 43
  • [27] Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
    Schnichels, Sven
    Hurst, Jose
    de Vries, Jan Willem
    Ullah, Sami
    Gruszka, Agnieszka
    Kwak, Minseok
    Loescher, Marina
    Dammeier, Sascha
    Bartz-Schmidt, Karl-Ulrich
    Spitzer, Martin S.
    Herrmann, Andreas
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2020, 29 (29)
  • [28] Unfulfilled Needs in the Detection, Diagnosis, Monitoring, Treatment, and Understanding of Glaucoma in Blacks Globally
    Adebayo, Ayobami
    Laroche, Daniel
    JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES, 2024, 11 (04) : 2103 - 2108
  • [29] The Treatment Exit Options for Uveitis (TOFU) Registry: Involving Patients in the Generation of Evidence
    Li, Jeany Q.
    Dell, Jennifer
    Holler, Tobias
    Fink, David
    Schmid, Matthias
    Heinz, Carsten
    Finger, Robert P.
    GESUNDHEITSWESEN, 2021, 83 : S39 - S44
  • [30] Targeted Drug Delivery Systems for the Treatment of Glaucoma: Most Advanced Systems Review
    Cegielska, Olga
    Sajkiewicz, Pawel
    POLYMERS, 2019, 11 (11)